Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Main Inclusion Criteria:~* History of asthma for at least 6 months~* Ability to show optimal use of MDI, including inhalation technique~* Lung function and reversibility within specified limits~Main Exclusion Criteria:~* Concomitant severe diseases~* Diseases which are contraindications for the use of inhaled steroids~* Two or more inpatient hospitalizations for asthma within the last year~* Respiratory tract infection or asthma exacerbation within the last 30 days prior to entry into the study~* Use of systemic steroids within the last 30 days prior to inclusion (depot steroids 6 weeks)~* Beginning of or change in immunotherapy within the last 6 months prior to inclusion~* Inability to follow the procedures of the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Ciclesonide 40 µg (Type: ACTIVE_COMPARATOR): Placebo-matching ciclesonide, inhaled via a metered-dose inhaler (MDI) with 1,1,1,2-hydrofluoroalkane (HFA)-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 40 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
- Ciclesonide 80 µg (Type: ACTIVE_COMPARATOR): Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 80 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
- Ciclesonide 160 µg (Type: ACTIVE_COMPARATOR): Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 160 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo-matching Ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 2 to 4 week in the Baseline period followed by placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).